Madeleine Johnson

The team and its partner SpectraPass are creating an assay with the intent of obtaining Emergency Use Authorization from the US Food and Drug Administration.

Inito is among a handful of diagnostics startups who have begun adding an ovulation confirmation target to fertility testing systems.

The Hopkins team expects to spinout a company soon in order to commercialize the technology in the next two to three years.

The firm expects to soon carve out a share in the rapidly expanding point-of-care, infectious disease, molecular diagnostics market.

Miniaturized sample-to-answer devices in development hint at an evolving molecular diagnostics landscape but launch timelines for these platforms remain unclear.

Four newly published PCR variant assays could potentially help health officials surveil communities and triage patients.

The firm expects an expanding market for at-home self-testing and is differentiating its products in part through their ease of use.

The firm plans to expand the menu for its immunoassay reader, anchoring its US expansion to a novel dual test for HIV and syphilis.

On a call with investors this week, the firm described massive revenue increases and discussed how it plans to sustain and deploy these gains.

After nearly a year in development, the firm's rapid antigen test will be submitted by the end of March for a prescription-use claim.